trending Market Intelligence /marketintelligence/en/news-insights/trending/jtf8bjscj_rkf4uufucghq2 content esgSubNav
In This List

Acasti Pharma regains Nasdaq compliance

Blog

Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share


Acasti Pharma regains Nasdaq compliance

Acasti Pharma Inc. said it regained compliance with a Nasdaq listing requirement that requires its shares to have a minimum bid price of $1.

The Canada-based developer of cardiovascular prescription drugs received the noncompliance notice in June.